Clinical Trial Costs in Emerging Geographies - Stephen Porter
•Download as PPT, PDF•
0 likes•824 views
![VDDI Pharmaceuticals ,[object Object],[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recommended
More Related Content
What's hot
What's hot (20)
Similar to Clinical Trial Costs in Emerging Geographies - Stephen Porter
Similar to Clinical Trial Costs in Emerging Geographies - Stephen Porter (20)
More from TTC, llc
More from TTC, llc (20)
Clinical Trial Costs in Emerging Geographies - Stephen Porter
- 1. Clinical Trial Costs in Emerging Geographies: China R. Stephen Porter, Pharm.D President, CEO and Chairman VDDI Pharmaceuticals Director & Co-founder Dragon Bio-Consultants, Ltd. Hong Kong, SAR
- 12. Market Attractiveness Matrix for Asia Country Patient Access Cost Market Opportunity Regulatory Approval timelines Australia ++ + +++ 2 - 3 months India +++++ ++++ ++ 3 -4 months China +++++ +++ +++++ 10 - 12 months Korea +++ ++ ++++ 3 - 4 months Taiwan ++ ++ ++ 3 – 4 months Singapore + ++ + 1- 2 months Indonesia +++ ++++ + 3 – 4 months Malaysia ++ +++ ++ 3 – 4 months Thailand +++ +++ + 3 – 4 months Philippines +++ ++++ + 3 - 4 months Vietnam +++ +++++ + 4 – 5 months
- 15. Blood Draw Source: GrantPlan® ( www.ttc-llc.com ) Procedure Country Flag Low (USD) Medium (USD) High (USD) Blood Draw USA 22 26 33 China 5 6 7 Hong Kong 7 7 10 Korea 5 6 7 Thailand 2 3 4 Taiwan 10 11 12
- 16. ECG Source: GrantPlan® ( www.ttc-llc.com ) Procedure Country Flag Low (USD) Medium (USD) High (USD) EC G USA 99 103 128 China 38 42 56 Hong Kong 32 47 49 Korea 14 21 34 Thailand 17 23 30 Taiwan 32 47 49
- 17. Initial Physical Exam (~60 min.) Source: GrantPlan® ( www.ttc-llc.com ) Procedure Country Flag Low (USD) Medium (USD) High (USD) Initial Physical Exam USA 202 239 260 China 61 97 151 Hong Kong 111 162 204 Korea 87 91 108 Thailand 53 67 80 Taiwan 55 98 101
- 18. Physical Exam (~15 min.) Source: GrantPlan® ( www.ttc-llc.com ) Procedure Country Flag Low (USD) Medium (USD) High (USD) Physical Exam USA 130 151 152 China 36 50 60 Hong Kong 63 88 105 Korea 40 48 55 Thailand 39 56 89 Taiwan 51 73 94
- 21. Contact Information Steve 斯蒂夫 R. Stephen Porter, CSO Dragon Bio-Consultants, Ltd. Suite 55, 5/F New Henry House, 10 Ice House Street Central, Hong Kong SAR HK Registered Company No.: 1429099 SKYPE: virtualdoc77 +86.15021242314 (Cell China) +1(615)445-5761 (Cell USA) http://dragonbio-consultants.com 香港中環 雪廠街 10 號 新顯利大廈 5 樓 55 室 香港公司註冊號碼： 1429099
- 22. Dragon Bio-Consultants, Ltd. Suite 55, 5/F New Henry House, 10 Ice House Street Central, Hong Kong SAR HK Registered Company No.: 1429099 SKYPE: virtualdoc77 +86.15021242314 (Cell China) +1(615)445-5761 (Cell USA) [email_address] http://dragonbio-consultants.com 香港中環 雪廠街 10 號 新顯利大廈 5 樓 55 室 香港公司註冊號碼： 1429099 VDDI Pharmaceuticals Chairman, President and CEO 115 Penn Warren Drive Suite 300-389 Brentwood, TN 37027 (615)445-5761 (cell) +86.15021242314 (Cell China) [email_address] http://www.virtualdrugdevelopment.com R. Stephen Porter, Pharm.D., FCP MRCP
Editor's Notes
- " Measures for the Administration of Drug Prices" is making its way through the NDRC. Early reports suggesting that off-patent originator pricing may be in jeopardy have set nerves on edge in the MNC Pharma sector. At the same time, the NDRC has reported that central drug bidding has caused unreasonable price increases, even as hospitals and distributors suggest that there have been insupportable price drops On the healthcare delivery front, the MOH has announced its intention to continue to reduce medical costs by regulating and standardizing medical practice which includes use of clinical pathways, prescription practice review, and elimination of excessive treatment/testing. China's new medical liability laws also contain prohibitions on unnecessary testing and diagnostics
- Thailand’s exempt for GPO!!! The rumor is that JnJ Shanghai may be involved in the latest SFDA